De novo variant in tyrosine kinase SRC causes thrombocytopenia: case report of a second family

Abstract

A germline heterozygous gain-of-function p.E527K variant in tyrosine kinase SRC was previously found to cause thrombocytopenia, myelofibrosis, bleeding, bone pathologies, premature edentulism and mild facial dysmorphia in nine patients of a single pedigree. Because of this variant, SRC loses its self-inhibitory capacity, causing constitutively active SRC expression in platelets. These patients have fewer and heterogeneous-sized platelets that are hyporeactive to collagen. We now report a 5-year-old girl with syndromic thrombocytopenia due to the same SRC-E527K variant that occurs de novo. A bone marrow biopsy, blood smear analysis, platelet aggregations, flow cytometric analysis of P-selectin, SRC expression and tyrosine phosphorylation studies were performed to confirm the similarities between the two families. This study strengthens our previous finding that hyperactive SRC kinase results in mild platelet dysfunction and thrombocytopenia with hypogranular platelets and further expands the clinical description of this syndrome to improve early recognition.

Keywords:

• Platelet dysfunction
• SRC
• thrombocytopenia
• tyrosine phosphorylation

Acknowledgements

KF and CVG have received a Chair from Bayer, CSL Behring, and SOBI.

Disclosure of interest

The authors report no conflicts of interest.

Supplementary Material

Supplemental data for this article can be accessed here.

Additional information

Funding

This work was supported by Chairs from Bayer [None]; CSL Behring [Heimburger grant]; SOBI [None].